X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
IT stocks in favour today 
(Fri, 19 Sep 11:30 am) 
 
After opening firm, the benchmark Indian Indices have continued to trade above the dotted line in the morning trading session. The software and realty stocks are the leading gainers in the pack. Stocks from FMCG, Capital goods sector are in red today.

The BSE-Sensex is trading up 30 points. The NSE-Nifty is trading up 16 points. The BSE Mid Cap index is trading up 0.4% and BSE Small Cap index is trading up 0.6%. The rupee is trading at 60.85 to the US dollar.

Most of the automobile stocks are trading higher today. Escorts Ltd and Eicher motors are leading the gainers. As per a leading business daily, automobile major Mahindra and Mahindra (M&M) has entered into deal with snapdeal for selling the new variant of Scorpio. This is a new trend seen in e-commerce site in India. Snapdeal has started accepting pre bookings for Scorpio. Reportedly, the new version of Scorpio will be unveiled on September 25. And this attempt by M&M's to use of an online channel will be viewed as an endorsement of the potential of e-commerce sites to drive sales volumes. After prebooking the new Scorpio on Snapdeal by paying Rs 20,000, customers can go to a dealer to make the full payment and take delivery.

Majority of Indian pharma stocks are trading firm with Panacea Biotech and Piramal Enterprises being among the leading gainers in the pack. As per the financial daily, the national pharmaceutical pricing authority (NPPA) has capped the prices of 19 medicines and their 43 different drug packs, including anti-infectives, gastro-intestinal drugs and vaccines. This move is expected to impact various Indian and MNC pharma companies like; Ranbaxy, Cipla, Cadila, Lupin. And among the MNC pharma companies Pfizer, and Sanofi. The latest tranche of price control includes key medicines such as ciprofloxacin, cefotaxime, BCG vaccine and rifampicin. Recently, the NPPA had brought all diabetes and cardiac medicines under indirect price control. The regulator is likely to extend the move to other categories, such as oncology, soon.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "IT stocks in favour today". Click here!

  
 

S&P BSE SENSEX


Jul 20, 2017 (Close)

MARKET STATS